Background: The goals of resection of functional neuroendocrine tumors (NETs) are two-fold: Oncological benefit and symptom control. The interaction between the two is not well understood.
| INTRODUCTION
Neuroendocrine tumors (NETs) consist of a heterogeneous group of tumors with distinct molecular, histological, and clinical features with complex and often challenging management strategies. 1 These tumors are traditionally divided as either functional or nonfunctional:
Functional NETs produce peptide hormones which cause symptoms, while nonfunctional NETs are typically clinically silent until they produce mass effect or bleed. Functional NETs are comprised of several histological types. In sporadic cases, the most common type is insulinoma, followed by gastrinoma and other types including glucagonoma, VIPoma, and somatostatinoma. 2 Each type is characterized by a discrete secretory phenotype and a predictable clinical syndrome. 3 The otherwise distinguishable clinical syndromes, however, can become muddied when functional NETs occur in the background of a hereditary tumor syndrome. These tumor syndromes, the most common being multiple endocrine neoplasia-I (MEN-I), provide unique challenges in the management of these patients. [4] [5] [6] [7] [8] [9] [10] For both sporadic and hereditary functional NETs, surgical resection provides the only potential for cure in patients with locoregional disease. Although NETs are generally indolent tumors, many patients undergo resection to relieve the clinical symptoms associated with functional NETs. 11 Aside from insulinomas which are commonly treated with enucleation, most functional NETs require a wide oncological resection with regional lymphadenectomy to achieve cure. 12, 13 Curative oncological resection, however, is not always possible, as many patients present with distant disease due to the propensity of these tumors to metastasize to the liver. Yet even in the metastatic setting, multiple groups have demonstrated that resection of liver metastases, cytoreductive surgery, and local ablative therapy may be associated with improved survival and alleviate symptoms of functional NETs. [14] [15] [16] These findings suggest a potential interaction between the relief of clinical symptoms of functional NETs, known as oncological parameters, disease recurrence, and survival.
Little information is available regarding the relationship between the achievement of hormone-specific symptom control and oncological benefit after the surgery for functional neuroendocrine tumors.
The aim of this study is to use a large, multi-institutional database to define the association between the failure to achieve symptom improvement after the surgical resection for functional neuroendocrine tumors and clinical outcomes. We also aimed to determine other clinicopathological factors associated with worse outcomes for functional NETs. Lastly, we aimed to establish the prognostic value of symptom improvement compared with other known oncological parameters.
| METHODS
Patients were identified using the United States Neuroendocrine 3 | RESULTS
| Demographics
Of 2181 total patients within the US-NETSG database, 230
patients underwent curative-intent resection of a functional NET.
Demographic characteristics are listed in Table 1 
| Perioperative data and pathology
The most frequent location for a functional NET in this cohort was in the pancreas (194, 84.3%), followed by the duodenum (26, 11.3%).
Perioperative and pathological characteristics are listed in Table 2 .
One-hundred and two (44%) patients underwent enucleation of their tumors, 26 of whom had lymph node retrieval with enucleation, and 128 (56%) patients underwent anatomic resection. There was no difference in RFS between patients who underwent enucleation versus those who underwent anatomic resection (P = 0.152). Table 4 . Multifocality, tumor differentiation, Ki-67 index, lymph node positivity, and lymphovascular/perineural invasion status were not associated with symptom improvement after the surgery.
| Symptom improvement and recurrence-free survival
On univariable analysis, factors associated with reduced RFS were noninsulinoma tumor histology (gastrinoma: HR 2.8, 95% CI, 1.3-6.1, P = 0.006, other: HR 2.7, 95% CI, 1.0-7.2 P = 0.042), having a known genetic tumor syndrome (HR 1.8, 95% CI, 0.9-3.5, P = 0.077), lymph node positivity (HR 1.8, 95% CI, 0.9-3.6, P = 0.080), R1 resection margin (HR 2, 95% CI, 1.0-3.9, P = 0.052), and failure of symptom improvement after the surgery (HR 3.1, 95% CI, 1.3-7.2, P = 0.008) ( Table 5 ). Tumor location, multifocality, and tumor differentiation were not associated with decreased RFS. On multivariable analysis, however, only the failure of symptom improvement was associated with decreased RFS (HR 4.7, 95% CI, 1.3-16.6, P = 0.016).
For this entire cohort, patients without symptom improvement had a lower 3-year RFS than patients who did experience symptom improvement (49.9% vs 80.3%, P = 0.005, Figure 1A) . When considering only patients with R0 resections, patients without symptom improvement continued to have a decreased 3-year RFS compared with patients with symptom improvement after surgery (36% vs 80%, P = 0.006; Figure 1B ). F I G U R E 1 Kaplan-Meier plots assessing the association between symptom improvement and recurrencefree survival. For all patients within the study cohort (A), the failure to achieve postoperative symptom improvement was associated with a significantly reduced recurrence-free survival. This remained true when examining only patients with R0 resection status on final pathologic assessment (B)
| DISCUSSION

